Overall consideration and comparative analysis of modified new drug in China and 505( b) (2) pathway drug application in the U. S.
GUO Can-hui
CAO Yu-ping
CHEN Cheng
BAI Yi-jun
YUAN Jing-chan
Machine-generated Keywords：
Publication Date：2022-03-31
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 532-535 )